Please login to the form below

Not currently logged in

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn

Rett syndrome and inherited amyotrophic lateral sclerosis (ALS) that are scheduled to start trials in late 2018 or early 2019. ... some big sellers like cancer drug Afinitor and Gilenya for multiple sclerosis in 2019, according to a report on

Latest news

More from news
Approximately 75 fully matching, plus 468 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    new ways of monitoring major depressive order, epilepsy and multiple sclerosis using wearable devices and smartphone technology. ... The innovative Medicines Initiative (IMI), with 5.3bn invested in 90 projects, is a barometer of the industry’s deep

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’Sandoz a tilt at the ... multiple channels in various geographies, which remains Mylan’s

  • Managing medication non-adherence Managing medication non-adherence

    efficacious. Biogen has been playing in this space for a few years now and conducted a clinical trial with PatientsLikeMe that showed how people living with multiple sclerosis (MS) can use

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes Mead Johnson's net debt of $1.2bn and represents a multiple of 17.4x 2016 non-GAAP EBITDA. ... The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab)

  • Deal Watch December 2016 Deal Watch December 2016

    inflammatory bowel disease and multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...